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Staphylococcus aureus Manganese Transport
Protein C Is a Highly Conserved Cell Surface
Protein That Elicits Protective Immunity
Against S. aureus and Staphylococcus
epidermidis
Annaliesa S. Anderson, Ingrid L. Scully, Yekaterina Timofeyeva, Ellen Murphy, Lisa K. McNeil, Terri Mininni,
Lorna Nuñez, Marjolaine Carriere, Christine Singer, Deborah A. Dilts, and Kathrin U. Jansen
Pﬁzer Vaccine Research, Pearl River, New York
Staphylococcus aureus and other staphylococci cause severe human disease, and there are currently no vac-
cines available. We evaluated whether manganese transport protein C (MntC), which is conserved across the
staphylococcal species group, could confer protection against S. aureus and Staphylococcus epidermidis.I n
vivo analysis of S. aureus MntC expression revealed that expression occurs very early during the infectious
cycle. Active immunization with MntC was effective at reducing the bacterial load associated with S. aureus
and S. epidermidis infection in an acute murine bacteremia model. Anti-MntC monoclonal antibodies have
been identiﬁed that can bind S. aureus and S. epidermidis cells and are protective in an infant rat passive
protection model and induce neutrophil respiratory burst activity. This is the ﬁrst description of a protein
that has the potential to provide protection across the staphylococcal species group.
Staphylococci cause diseases ranging from relatively
mild superﬁcial skin infections to life-threatening
conditions, including sepsis and endocarditis. Increas-
ingly, staphylococci have developed antibiotic resist-
ance, reducing treatment options and highlighting the
need for an effective prophylactic vaccine. Preclinical
studies have assessed several antigens that, either alone
[1, 2] or in combination [3], have the ability to reduce
staphylococcal disease in preclinical models. Staphylo-
coccal strains are known for the phenotypic plasticity
of their antigenic repertoire, which provides
mechanisms for both survival in diverse host niches
and for immune evasion. Thus the development of a
broadly protective vaccine that can prevent different
diseases caused by diverse strains from within the
species group poses challenges.
S. aureus distinguishes itself from other staphylo-
cocci by an impressive array of virulence factors [4]
and the production of coagulase. S. epidermidis also
causes disease with associated mortality [5, 6]. S.
aureus and S. epidermidis share a core genome repre-
senting approximatly two thirds of their genes; the
proteins encoded by the core genesaverage 70% amino
acid sequence identity between the two organisms [4].
We were interested in evaluating proteins with the
potential to prevent staphylococcal disease caused by
either S. aureus or S. epidermidis.
Effective bacterial vaccine components should be con-
served and perform important functions during infec-
tion. Initial attempts to identify S. aureus vaccine
candidates came from assessment of surface antigens
from bacteria grown in vitro [7] .A d v a n c e si ni nv i v o
technology have led to a better understanding of
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knowledge of host-pathogen relationships. When S. aureus and
other pathogenic bacteria invade, they initiate expression of mul-
tiple virulence pathways. S. aureus produces capsular polysac-
c h a r i d et oa v o i da t t a c kf r o mt h ei n n a t ei m m u n es y s t e m .I ta l s o
expresses various ligand-binding proteins with roles ranging
from immune cloaking [8] to scavenging essential ions [9]. One
group of proteins associated with in vivo survival of S. aureus are
the manganese transport (Mnt) proteins. The Mnt complex is an
ABC transporter composed of an ATP-binding protein (MntA),
an integral membrane transporter (MntB), and a manganese
binding surface lipoprotein (MntC) [10]. Recently MntC was
identiﬁed as being expressed on the cell surface of S. aureus in
bioﬁlms generated in in vivo models of infection [11].The ortho-
logous protein in S. epidermidis is staphylococcal iron transport
C( S i t C )[ 12], which was detected in convalescent-phase serum
from rabbits infected with S. epidermidis and found to be protec-
tive in a S. epidermidis murine kidney abscess model [13].
A critical attribute for an effective staphylococcal vaccine
antigen is early expression during infection, which provides an
opportunity for vaccine-induced antibodies to inactivate bac-
teria before infection is ﬁrmly established. We therefore evalu-
ated S. aureus MntC temporal expression in vivo. S. aureus
MntC and S. epidermidis SitC have a high level of sequence
identity (72%), and polyclonal antisera have been demons-
trated to be cross-reactive [13]. We explored whether S. aureus
MntC could produce cross-protective antibodies against both
S. aureus and S. epidermidis infection.
MATERIALS AND METHODS
Bacterial Strains
S. aureus strains Mu50 and Newman were used for cloning
and MntC ﬂow cytometry studies, respectively. The S. aureus
strains used for in vivo evaluations are listed in Table 1.
S. aureus clinical isolates described in [14] were used to deter-
mine mntC sequence variability. S. epidermidis strain 0–47
[15] was used to assess cross protection. Staphylococcal cul-
tures were grown in a Chelex-treated TSB medium for MntC/
SitC in vitro expression.
Cloning of Recombinant Antigens
mntC (SAV0631) from S. aureus Mu50 chromosomal DNA was
ampliﬁed by polymerase chain reaction (PCR), using primers
5′-TTTCTTCCATGGGTACTGGTGGTAAACAAAGCAG-3′
and 5′-TTTCTTGCTCAGCATTATTTCATGCTTCCGTGTA
CAG-3′ containing NcoI and BlpI sites, respectively. The PCR
product was cloned into NcoI- and BlpI-cleaved pET28a vector
(Novagen) to create pLP1215, which was transformed into Es-
cherichia coli strain BLR(DE3) (Novagen) to generate strain
PVPR-161, used for recombinant protein expression. IsdB and
IsdA were cloned and expressed as described previously [1,16].
Nucleotide Sequencing
Isolates were grown in tryptic soy broth (5 mL) for 3–5 hours.
Pelleted bacteria were resuspended in 200 µL lysis buffer
(50 mM Tris-HCl pH 7.5, 145 mM NaCl, 0.1 mg/mL
Table 1. Characteristics of Staphyloccocus aureus Isolates Used for This Investigation and Detection of Manganese Transport
Protein C (MntC), IsdA, and IsdB During Bacteremia
CP8 strain, methicillin resistance, ST/CC CP5 strain, methicillin resistance, ST/CC
0003 0182 0101 0186 0155 0210 0158 0140 Reynolds 0212
Yes No Yes No No Yes No No No Yes
Antigen Time (h) 88/78 51/51 255/78 57/30 26/25 231/5 28/25 9/9 25/25 235/235
MntC 0 −− − −−−+ −− +
1+ − ++ + + − ++ −
4 ++ + +++++ + +
6+ + − ++− ++ + +
IsdB 0 −− − −−−−− − −
1 −− − −−+ −− − −
4 −− − −−−+ −− −
6 ++ + +++++ + −
IsdA 0 −− − −−−−− − −
1 −− − −−−−− − −
4 − ++− + −−− + −
6+ + − −−−−− − +
Each S. aureus isolate was used to infect 9 mice. At each time point (1, 4, and 6 hours) after infection, 3 mice were sacrificed, the blood pooled, and the bacteria
isolated. The bacteria at the time of challenge (in vitro: T0) and after isolation from the bloodstream (in vivo: T1, T4, and T6) were analyzed by
immunofluorescence microscopy. The experiments for each isolate were repeated 3 times.
Abbreviations: CC, clonal complex; ST, sequence type; +, antigen was expressed by majority of the bacterial cells; −, undetectable antigen expression on
bacterial cells.
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Blood and Tissue kit (QIAGEN). Sequencing of mntC was
performed using the following primers: 5′-CACAAAATTT
ACGAATAGAAAGAAACGAG-3′ and 5′-AAAATATTGGA
GATACCAATATTTTAGGTTG-3′ (PCR) and 5′-ACAAACA
TTTATCGATAACGAC-3′ and 5′-GAGCAATGTATTTGTT
ACCTTG-3′ (sequencing). SAV0631 was used for the refer-
ence sequence.
Expression and Puriﬁcation of Recombinant MntC
Recombinant MntC was produced in E. coli by fed batch fer-
mentation in minimal medium at 35°C. Protein expression
was induced by the addition of 0.1 mM IPTG. Cells were har-
vested by centrifugation and disrupted by microﬂuidization at
15000 psi. The soluble fraction was clariﬁed by polyethylenei-
mine ﬂocculation. Protein was puriﬁed using a sulfopropyl
sepharose column followed by a phenyl sepharose column.
The resulting protein was >95% pure.
Generation of Rabbit Immune Sera
New Zealand White female rabbits (Charles River Canada)
were vaccinated intramuscularly at weeks 0, 4, and 9 with
20 μg MntC, IsdA, or IsdB formulated with AlPO4. Serum
samples were collected at weeks 0 and 10.
Monoclonal Antibodies
Hybridomas were generated from a fusion of a nonsecreting
myeloma cell line (X63Ag8.653, ATCC) with splenocytes that
were harvested from mice immunized with puriﬁed recombi-
nant MntC. Anti-MntC–secreting hybridomas were selected
by MntC protein and SitC protein enzyme-linked immunosor-
bant assays, using standard procedures, and ﬂow cytometry.
Flow Cytometry
S. aureus strain Newman was grown in Chelexed TSB medium
for 18 hours. Bacteria were killed (60°C, one hour), then ﬁxed
in 1% paraformaldehyde. Bacteria were then blocked in heat-
inactivated porcine sera (10%)(PS)/Phosphate buffered saline
(PBS) (JR Scientiﬁc Inc), then transferred to a 96-well U-
bottomed polystyrene plate (100 µL per well). Cells were
washed with porcine serum in phosphate-buffered saline
(PBS) prior to adding anti-MntC monoclonal antibodies or an
isotype control (Jackson Immunoresearch). Cells were then
washed in PBS and incubated on ice with biotinylated goat
anti-mouse immunoglobulin G (IgG; Jackson Immunore-
search). Cells were washed with PBS and incubated on ice
with streptavidin-phycoerythrin (BD Biosciences). After a
ﬁnal wash step, the cell pellets were resuspended in 1% paraf-
ormaldehyde. A total of 20000 events/well were acquired on a
BD LSR II ﬂow cytometer and analyzed using FlowJo software
(Treestar). The mean ﬂuorescence intensity (MFI) was deter-
mined for each sample after gating on bacteria. An MFI was
considered positive if it was ≥3 times that of the control anti-
body MFI and >100.
Epitope Mapping by Surface Plasmon Resonance
Interference epitope mapping by surface plasmon resonance
with a BIACore instrument was performed as described by
Johne et al [17]. Brieﬂy, rat anti-mouse Fc antibodies (Thermo
Scientiﬁc) were immobilized to CM5 Series S sensor chips (GE
Healthcare) with NHS/EDC (GE Healthcare). All monoclonal
antibodies (mAbs) and MntC were diluted in HBS-EP (GE
Healthcare). After rat anti-mouse IgG immobilization, a 2-μM
solution of primary test mAb was injected. Each ﬂow cell
bound at least 300 RU of mAbs. Once all 4 ﬂow cells were
populated by a speciﬁc mAb, unoccupied rat-anti-mouse Fc
was blocked using normal mouse serum. MntC (2 μM) was in-
jected into the ﬂow cells and allowed to form a stable MntC-
primary mAb complex for 4 minutes. The 4 test secondary
mAbs were added to the mAb-MntC complexes, 1 per ﬂow
cell, and the level of binding measured in a BIACore T100 (GE
Healthcare) and analyzed using BIAevaluation version 4.1 soft-
ware (GE Healthcare). Monoclonal antibodies were classiﬁed
as noncompetitive if they yielded an RU of >99.
Monitoring In Vivo Expression During Murine Bacteremia
CD1 mice (Charles River Laboratories, Wilmington, MA)
were infected by intraperitoneal injection of approximately
2×10
8 colony-forming units (CFU) of S. aureus grown to
OD600 of approximately 2.5 in tryptic soy broth (Sigma
Chemical Company, St. Louis, MO). Mice were exsanguinated
at 1, 4, and 6 hours after infection, and blood from 3 mice was
pooled into ice-cold 0.4% sodium citrate, pH 7.0. Eukaryotic
cells were lysed by sonication. The bacteria were washed with
PBS and were deposited on microscope slides. Slides were in-
cubated overnight at 4°C with primary rabbit antibodies at 5
µg/mL and detected with ALEXA488-conjugated goat-
α-rabbit antibody (1:250, Invitrogen, Carlsbad, CA). A cover-
slip was then mounted with VectaShield HardSet medium
(Vector Laboratories, Burlingame, CA). Images were obtained
using an Olympus BX60 light/ﬂuorescent microscope with a
60× oil immersion objective and EM-CCD Hamamatsu
camera mounted in the optical path of the microscope
(Olympus, Center Valley, PA) for both DIC and ﬂuorescence.
MetaMorph Software (Universal Imaging, Sunnyvale, CA) was
used to acquire images.
Murine Bacteremia Model
Groups of 10 CD-1 mice (Charles River Laboratories, Wilming-
ton, MA) were vaccinated at weeks 0, 3, and 6 with 10 µg MntC
+22µgAl P O 4, followed by intraperitoneal challenge on week 8
with 5×10
8 CFU S. aureus Reynolds or S. epidermidis O-47.
Animals were exsanguinated 3 hours after challenge, and serial
dilutions of blood were plated to enumerate recovered bacteria.
1690 ￿ JID 2012:205 (1 June) ￿ Anderson et alStatistical signiﬁcance was determined via the Student t test, and
a P value of ≤.05 was considered signiﬁcant.
Respiratory Burst Assay
HL-60 cells (40000) were differentiated with dimethylforma-
mide and mixed with S. aureus PFESA PFESA0186 or S. epi-
dermidis 0–47 cells (2000 CFU), rabbit complement (Pel-
Freez, Rogers, AZ), and test mAb (10 µg). For the speciﬁcity
test, recombinant MntC (20 µg) was also added. Kinetic res-
piratory burst activity was measured every 5 minutes for up to
90 minutes by luminol (TCI America, Portland, OR) chemilu-
minescence in a Luminoskan Ascent (Thermo Scientiﬁc,
Waltham, MA).
Infant Rat Passive Immunization Model
Groups of Sprague-Dawley infant rats (Charles River Labora-
tories, Wilmington MA) were immunized intraperitoneally
with 0.4 mg of either test mAb or isotype control mAb.
Sixteen hours after immunization, rats were challenged intra-
peritoneally with 1 ×10
8 CFU of a S. aureus clinical isolate,
PFESA0140. Four hours later, blood was collected, and serial
dilutions were plated to enumerate recovered bacteria. Statisti-
cal signiﬁcance was determined via the Student t test, and a
P value of ≤.05 was considered signiﬁcant.
All animal studies were conducted according to Insti-
tutional Animal Care and Use Committee guidelines.
RESULTS
MntC Is Highly Conserved Among Diverse S. aureus Clinical
Isolates
We evaluated the MntC distribution and sequence heterogen-
eity from 3 collections of S. aureus clinical isolates (n= 289)
that deﬁne the breadth of S. aureus disease-causing strains.
The ﬁrst collection represented the diversity of both current
and historical S. aureus isolates, with an emphasis on maximiz-
ing the diversity of multilocus sequence typing (MLST)
lineages; the second collection represented a prevalence set of
recently circulating clinical isolates from the Centers for
Disease Control and Prevention [14, 18]; an additional 65
strains from Pﬁzer’s collection were also included. Overall, 90
different sequence types in >25 MLST clonal complexes were
represented. MntC was found to be highly conserved: only 8
different protein sequence variants were identiﬁed, and a single
variant (MntC_001, the vaccine antigen) was found in 88% of
these strains. One isolate (NCTC8325) had an insertion of 3
amino acids at residue 190, and the other 6 sequences differed
from the reference sequence by ≤2 amino acids. We also inves-
tigated the distribution and divergence of MntC orthologs
among other Staphylococcus species (Table 2). The MntC
orthologs were somewhat conserved, with an average protein
pairwise identity of 75%, ranging from 66% to 94%. The 2
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Novel Antistaphylococcal Vaccine ￿ JID 2012:205 (1 June) ￿ 1691closest orthologs were present in Staphyloccocus hominis and
Staphyloccocus haemolyticus, the most distant was in Staphylo-
coccus pseudintermedius. SitC, the S. epidermidis ortholog of
MntC, was 77% identical to S. aureus MntC.
MntC Is Expressed on the Cell Surface In Vivo Early During
Infection
The in vivo expression of S. aureus ion-scavenging proteins
MntC, IsdA, and IsdB was investigated in a murine bacteremia
model, using 10 S. aureus isolates. Bacteria were harvested at
various time points after infection, and antigen expression was
assessed without further culture by immunoﬂuorescence
microscopy. The antigens were sparsely expressed, if at all, by
the in vitro grown cells used to infect the mice. Analysis of the
temporal in vivo antigen expression revealed that MntC was
rapidly upregulated in vivo during bacteremia, with 7 of 10
strains expressing MntC on the surface by 1 hour and all
strains expressing MntC by 4 hours. In contrast, only 1 strain
expressed IsdB 1 hour after infection, and no strains tested ex-
pressed IsdA at this time point (Table 1; Figure 1).
Active Vaccination With MntC Reduces S. aureus and
S. epidermidis Bacteremia in a Murine Bacteremia Model
Active immunization experiments were conducted to deter-
mine whether a MntC vaccine could reduce S. aureus bactere-
mia in mice. Mice were vaccinated 3 times with MntC and
then challenged with S. aureus Reynolds. A signiﬁcant
reduction in the number of bacteria recovered from the blood
3 hours after challenge was observed. The experiment was re-
peated an additional 9 times. In all experiments, fewer bacteria
were recovered from the blood of MntC-vaccinated animals
than from the blood of controls (Table 3). For 6 of the 10
experiments, this reduction was statistically signiﬁcant. Meta-
analysis of all 10 experiments demonstrated that vaccination
with MntC signiﬁcantly reduced bacteremia, compared with
observations for controls (P<.0001).
MntC and its S. epidermidis ortholog SitC are 77% identical,
and sera against SitC can cross-react with MntC [13]. There-
fore, the effect of immunization with MntC against heter-
ologous S. epidermidis challenge was also explored in the
bacteremia model. Mice were vaccinated 3 times with MntC
and then challenged intraperitoneally with S. epidermidis
0–47. Immunization with MntC resulted in a signiﬁcant
Figure 1. Visualization of antigen expression by Staphylococcus
aureus PFESA0155 during bacteremia. In this strain, manganese transport
protein C (MntC) is expressed rapidly after infection and remains ex-
pressed throughout the experiment. In contrast, IsdA expression is
delayed and not continuous throughout the experiment. The expression
proﬁles for additional clinical isolates are given in Table 1. Three groups
of 3 mice each were infected by intraperitoneal injection of 5×10
8
colony-forming units of the S. aureus clinical isolate PFESA0155. At 1, 4,
and 6 hours after infection, one group was sacriﬁced, blood from the
animals was pooled, and the bacteria were isolated. Bacteria at the time
of challenge (T0) and bacteria isolated from the bloodstream (T1, T4, and
T6) were stained with afﬁnity-puriﬁed rabbit anti-MntC, anti-IsdA, or
control immunoglobulin G and visualized with a ﬂuorescent microscope.
A, Differential interference contrast (DIC) images of anti-MntC smears.
B, Fluorescence microscopy images of MntC expression. C, DIC images
of anti-IsdA smears. D, Fluorescence microscopy images of IsdA
expression.
Table 3. Immunization With Manganese Transport Protein C
Reduces Recovered Colony-Forming Units (CFU) in a Murine Bac-
teremia Model
Challenge
Staphylococcal
Organism,
Experiment
No. of
Animals
Log CFU
Reduction of
Mean vs Control
Mean P
S. aureus
1 10 1.2 .0056
2 10 1.6 .0002
3 10 0.81 .0544
4 10 1.38 .0055
5 10 0.47 .1367
6 10 0.83 .0090
7 10 0.74 .0444
8 10 0.75 .0180
9 10 0.41 .3066
10 10 0.59 .0882
Meta-analysis 100 0.955 <.0001
S. epidermidis
1 10 0.87 .0291
2 10 1.02 .0229
Meta-analysis 20 0.95 .0013
Groups of female (5–6-week-old) CD1 mice were vaccinated by
subcutaneous injection with either saline or 10 µg MntC in 22 μg AlPO4 as
adjuvant. Two weeks after the last immunization, mice were challenged by
intraperitoneal injection of approximately 5 × 10
8 CFU of either S. aureus
strain Reynolds or S. epidermidis 0-47. Three hours after challenge, animals
were sacrificed and the bacteria in the blood enumerated. Experiments with
statistically significant results are in bold.
1692 ￿ JID 2012:205 (1 June) ￿ Anderson et alreduction in bacterial blood levels for 2 independent studies
(Table 3). This demonstrates that MntC could potentially
cross-protect against S. epidermidis infection.
Demonstration of MntC Antibody-Mediated Protection
Murine anti-MntC mAbs were made using the MntC vaccine.
These antibodies fell into 1 of 4 patterns: (1) cross-reactive to
both MntC and SitC protein and binding to native protein on
the cell surface, (2) reactive to MntC only and binding to
native protein on the cell surface, (3) cross-reactive to both
MntC and SitC, with no binding to surface-exposed epitopes,
and (4) reactive to MntC only with no binding to surface-
exposed epitopes (Figure 2). A representative selection of
mAbs from each of the 4 patterns was evaluated by BIACore
to determine antigen-binding interference groups (Figure 2).
A sandwich approach was used, in which the primary test
mAb was attached to the chip and used to capture MntC and
then a secondary mAb was applied. This established whether
the 2 mAbs recognized the same or different regions of the
protein. The antibodies were grouped into 3 interference
groups representing 3 independent mAb-binding regions.
These interference groups all contained mAbs from pattern 1
that could recognize MntC on the cell surface of S. aureus and
cross-reacted with the S. epidermidis ortholog SitC. Mono-
clonal antibodies that did not recognize the native MntC
antigen on the cell surface of S. aureus and therefore did not
recognize relevant epitopes could not be mapped by Biacore
because they were unable to capture the protein when pre-
sented in a soluble matrix, underscoring the importance of
monitoring antibody binding to native antigens on the bac-
terial cell surface.
Both an in vivo passive protection model and an in vitro
respiratory burst assay were used to assess the functionality of
anti-MntC antibodies. Antibodies from all 3 binning groups
were tested for their ability to be protective in the infant
rat model and were able to reduce the bacteremia, com-
pared observations for controls (Table 4; data not shown for
interference group1). Enhanced neutrophil respiratory burst
activity was observed for the anti-MntC mAbs using both S.
aureus and S. epidermidis strains; this was abrogated by pre-
incubation with MntC, indicating that the response is speciﬁc
to antibody binding to MntC (Figure 3).
DISCUSSION
Many antigens have been evaluated in the search to ﬁnd a
vaccine with the potential to protect against staphylococcal
disease [7]. In this study, we provide preclinical evidence for
the inclusion of MntC as a component of a multiantigen pro-
phylactic antistaphylococcal vaccine. Staphylococci are
Figure 2. Characterization of anti–manganese transport protein C
(MntC) monoclonal antibodies (mAbs). Reactivity patterns of anti-MntC
mAbs (A) and binding interference patterns detected by BIAcore (B). A,
The 23 mAbs generated were grouped into 4 distinct patterns, by reactiv-
ity to MntC and SitC protein in enzyme-linked immunosorbant assays,
and to MntC on the cell surface of Staphyloccocus aureus, by ﬂow cyto-
metry. B, The overlapping ellipses display interference by BIACore analy-
sis. Pattern numbers of the mAbs are indicated within the ellipses,
which represent antibody interference space and are arbitrary in size.
The 3 interference groups are identiﬁed.
Table 4. Passive Immunization With Anti–Manganese Transport
Protein C Monoclonal Antibodies Signiﬁcantly Reduces Recov-
ered Colony-Forming Unites (CFU) in an Infant Rat Model of
Infection
Passive
Immunization
(Interference
Group)
No. of
Animals
Mean (95% CI) Log
CFU/mL Blood
P vs IgG1
Control
305-78-7 (2) 10 3.40 (2.73–4.05) .0053
305-101-8 (3) 10 3.64 (3.13–4.14) .0082
IgG1 control 10 4.40 (4.12–4.67)
PBS 10 4.40 (4.04–4.76) NS
The rats were passively immunized by intraperitoneal injection with either
saline or 0.4 mg of monoclonal antibodies 16 hours before they were
challenged by intraperitoneal injection with approximately 1 × 10
8 CFU of
Staphyloccocus aureus PFESA0140. At 4 hours after challenge, the animals
were sacrificed and the bacteria in the blood enumerated. The antibody mAB
interference groups as identified by BIACore are noted.
Abbreviations: CI, confidence interval; IgG1, immunoglobulin G1; NS, not
significant; PBS, phosphate-buffered saline.
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is attributable to the expression of virulence factors such as
polysaccharide capsules that enhance their survival and to the
formation of bioﬁlms. Seminal studies by Burke [19] demon-
strated that presurgical antibiotic prophylaxis is only effective
when administered in a time frame that maintains the drug in
the bloodstream prior to and during surgery, the time at
which the patient becomes infected with the bacteria. Anti-
biotic prophylaxis administered after this critical period is less
effective in preventing infection. Therefore, we hypothesize
that a vaccine will have the highest probability of success if
antibodies can engage and eliminate the bacteria during this
early phase of infection. The identiﬁcation of an antigen that
induces a protective effect and is expressed early during infec-
tion is a critical attribute for an antistaphylococcal vaccine in
order to prevent a full-blown infection and bacterial persist-
ence. We have generated evidence that the manganese trans-
porter MntC is such an antigen. Staphylococci require trace
elements such as manganese for growth. However, such ions
become toxic when present in excess [20], so manganese
uptake is highly regulated. While these uptake systems are not
expressed during in vitro growth in nutrient-rich conditions,
they are rapidly upregulated to aid bacterial survival in vivo.
In contrast to MntC, IsdA and IsdB, which are also under
evaluation for vaccine development [16, 21, 22], were detected
on the cell surface much later in vivo, if at all (Table 1;
Figure 1). This is in agreement with the ﬁndings of Cheng
et al [23], who demonstrated, using isogenic strain sets carry-
ing IsdA or IsdB deletions, that neither protein was required
for early infection events but that both were required for
events occurring later in infection, such as abscesses
formation.
Manganese may also play a role for S. aureus in immune
evasion by protecting the bacteria from neutrophil attack,
which will occur once antibodies interact with the bacteria in
the bloodstream. A primary mechanism for bacterial killing
Figure 3. Anti–manganese transport protein C (MntC) antibody 305-78-7 induces neutrophil respiratory burst activity against both Staphyloccocus
aureus and Staphyloccocus epidermidis. HL-60 neutrophil-like cells were incubated with bacteria and a source of complement alone, or with bacteria,
complement, and anti-MntC antibodies (closed symbols). Respiratory burst activity was measured by chemiluminescence in a kinetic manner, with
reads every 5 minutes. A, The anti-MntC antibody 305-78-7 was able to elicit a robust respiratory burst against S. aureus (closed symbols), which was
abrogated by preincubation with MntC protein (open symbols). B, An irrelevant isotype controlled antibody was not able to elicit a robust respiratory
burst against S. aureus (closed symbols), and preincubation with MntC protein demonstrated only a minor reduction of respiratory burst activity (open
symbols). C, The anti-MntC monoclonal antibody (mAb) 305-78-7 was also able to elicit a respiratory burst against S. epidermidis, compared with an
irrelevant control antibody. Abbreviation: RLU, relative light units.
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the ingested pathogen. In vitro assays have demonstrated that
S. aureus can neutralize these agents with either manganese
alone [10] or with superoxide dismutases that require manga-
nese as a cofactor [24, 25]. It is therefore plausible that
S. aureus uses these mechanisms to evade killing in the phago-
some, upregulating MntC and acquiring manganese early
during infection. Anti-MntC antibodies therefore may have
the potential to interfere with the bacteria’s ability to evade
this critical immune defense mechanism, an aspect that war-
rants further investigation.
Both the MntC vaccine and anti-MntC mAbs were protec-
tive in several animal models of infection. To investigate
whether the mechanism was related to opsonophagocitic
killing, we developed a respiratory burst assay and demon-
strated that anti-MntC antibodies bound to S. aureus and
S. epidermidis cells can induce a neutrophil respiratory burst
that is an important indicator of neutrophil activation and
initiation of the bacterial killing cascade. Speciﬁcity of the re-
action was demonstrated by the addition of recombinant
MntC to the reaction, which prevented the binding of the
MntC antibodies to the bacteria. The respiratory burst assay
was conducted in place of an opsonophagocytic assay (OPA),
which measures antibody- and complement-mediated bac-
terial killing. OPAs require in vitro antigen expression, and
MntC is elaborated only under manganese-free conditions
that render the cells fragile and susceptible to nonspeciﬁc kill,
thus precluding the OPA to monitor antibody function. The
neutrophil respiratory burst is recognized as an important
mechanism for bacterial killing, as evidenced in patients with
chronic granulomatous disease, who lack neutrophil respirat-
ory burst activity and are at increased risk of infection [26].
Previous studies had demonstrated that anti MntC anti-
bodies are cross-reactive across different staphylococcal species
[13]. The highly conserved nature of this protein family
(Table 2) led us to examine the potential for S. aureus protein
antigens to cross-protect against S. epidermidis (Table 4). This
is the ﬁrst demonstration of such cross-protection in the litera-
ture and offers exciting prospects for future vaccine develop-
ment for the prevention of staphylococcal diseases.
In recent years, 2 vaccines designed to prevent S. aureus in-
fections have not progressed past phase III clinical trials [7].
The ﬁrst was a bivalent conjugate polysaccharide conjugate
vaccine [27], and the second contained the iron-binding
protein IsdB [22]. Both vaccines presented preclinical and
early clinical data that suggested efﬁcacy but were not substan-
tiated during phase III studies. A drawback for both of these
approaches was that the vaccines were based on a single com-
ponent (capsular polysaccharide or IsdB), and in vivo
expression data have shown that single antigens may not be
expressed by all strains [28] or early enough during infection
(Table 2) to eliminate bacteria early in the infection cycle.
Furthermore, in a preclinical model of infection, Stranger-
Jones et al [3] demonstrated that indeed multiple antigens are
required for more robust protection. Taking all data together,
a vaccine will need to include multiple bacterial antigens to be
effective against these challenging pathogens, and antigen
expression will need to occur early during infection. We have
described the potential usefulness of MntC as a vaccine com-
ponent on the basis of 4 major attributes of critical impor-
tance: early expression during infection, an essential role for
the protein in vivo, protection in preclinical models of infec-
tion, and potential cross-protection against other staphylococ-
ci. MntC is currently in clinical trials as a component of a
multiantigen vaccine that includes capsule polysaccharide con-
jugates and clumping factor A (ClinicalTrials.gov registry
number NCT01364571) and has the potential to contribute to
the prevention of S. aureus disease, thus fulﬁlling a signiﬁcant
unmet medical need.
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